Monday, November 16, 2026
23.3 C
Bengaluru

India’s Patent Revocations: Strengthening Access and Challenging Evergreening

The Indian Patent Office’s recent decision to revoke Novartis’ patent on the cardiac drug Vymada marks another chapter in the country’s robust stand for patient access against the tide of patent evergreening. At the heart of this and previous landmark cases lies Section 3(d) of the Indian Patent Act—a provision designed to ensure genuine innovation while preventing minor, incremental changes from being used to unjustly extend patent monopolies.

Landmark Cases: A Timeline

  • Novartis v. Union of India (Glivec/Imatinib Mesylate): In 2013, the Supreme Court of India rejected Novartis’ application to patent a beta-crystalline form of the anti-cancer drug Glivec. The court ruled that the new version did not meet the higher bar of “enhanced efficacy” required by Section 3(d), and thus could not be patented. This decision was hailed by patient groups and humanitarian organizations for preserving affordable generic access, with the cost of generics being a fraction of branded Glivec’s price.[1][2][3][4][5]

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

Topics

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

The Innovator’s Gene and the Generic’s Promise

A medicine must first be discovered. It must then...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...
spot_img

Related Articles

spot_imgspot_img